A mid-stage clinical study of RAP-219 is delivering striking results for adults with drug-resistant focal epilepsy, a group that often cycles through multiple medicines with limited relief. As first reported by New Atlas, investigators observed large drops in seizure activity, including a median 77.8% reduction in clinical seizures over eight weeks and seizure-freedom for nearly a quarter of participants—rare outcomes in such a hard-to-treat population.
Who’s behind the progress
The program is led by Boston-based Rapport Therapeutics, a neuroscience biotech developing precision small-molecule medicines. In its official announcement, the company reported that RAP-219 met its primary endpoint—reducing objective “long episodes” captured by implanted neurostimulator devices—and was generally well tolerated. Rapport says it plans two Phase 3 trials following regulatory consultation. You can read the sponsor’s details in the Rapport Therapeutics press release.
Academic leadership matters here, too. The multicenter study includes investigators from NYU Langone Health, where epilepsy specialist Jacqueline French, MD has emphasized the trial’s novel use of continuous electrophysiology from responsive neurostimulation (RNS) systems to anchor endpoints. Coverage in NeurologyLive highlights both the magnitude of the seizure reductions and the objective biomarker approach—an advance that helps translate lab insights into clinical decisions.
Finally, transparency on the protocol and sites comes via public trial registries. The study—NCT06377930—is listed on CenterWatch as an open-label, proof-of-concept trial in 30 adult participants with refractory focal epilepsy, all implanted with RNS for continuous recording. Basic design elements and eligibility criteria are summarized on CenterWatch.
What makes RAP-219 different—and why that’s good news
Most anti-seizure medications act broadly on neuronal excitability, which can curb seizures but also bring sedation, cognitive fog, or motor side effects. RAP-219 was built with a more anatomically selective idea in mind: it modulates AMPA receptors through TARPγ8, a regulatory subunit that is enriched in brain regions—like the neocortex and hippocampus—where focal seizures commonly arise. That targeting is the rationale for achieving strong seizure control while potentially avoiding the “whole-brain” downsides that limit many therapies. Early signals in the trial support this: the drug reduced the study’s objective biomarker of pathologic activity (long episodes) and achieved sizable clinical seizure reductions, with mostly mild to moderate adverse events reported by the sponsor.
Beyond one drug, the study’s method is a win for patients. Using implanted RNS devices to quantify abnormal electrical bursts gives researchers real-time, objective measures that correlate with clinical seizures. That helps de-risk development and makes success (or failure) clearer earlier—potentially speeding useful medicines to people who need them.
Where this could lead next
For people living with uncontrolled focal seizures, any sustained drop in frequency can be life-changing—protecting employment, independence, safety, and mental health. The RAP-219 data point to a credible new option if larger, controlled studies confirm both efficacy and tolerability. According to NeurologyLive, Rapport plans a formal meeting with regulators and expects to start two pivotal studies, a standard path toward potential approval if outcomes hold.
Overall, this moment is encouraging without hype: a purpose-built medicine, a thoughtful clinical design, and collaboration between a biotech sponsor and academic leaders are combining to push the frontier of epilepsy care. If the Phase 3 results echo what’s been seen so far, people with drug-resistant focal epilepsy could soon have a treatment that is both effective and precise—and that’s good news.
More Good News
-
Senegal launches all-electric bus network powered by renewable energy
Senegal has successfully launched a transformative Bus Rapid Transit system in Dakar, featuring a fleet of 121 fully electric buses. As the first network in Sub-Saharan Africa to operate entirely on renewable energy, the initiative utilizes local solar power to transport up to 300,000 passengers daily. By utilizing dedicated lanes, the clean energy fleet cuts cross-city commute times in half while preventing nearly 60,000 tons of carbon dioxide emissions annually. This monumental project dramatically improves urban air quality and establishes Senegal as a pioneering leader in sustainable, green public infrastructure.
-
Yangtze River showing remarkable ecological recovery following fishing ban
China’s Yangtze River is experiencing a remarkable ecological revival five years into a sweeping ten-year commercial fishing ban. Recent surveys reveal significant increases in overall fish biomass and the heartening return of critically endangered species in the world’s fifth largest river. Furthermore, thousands of former commercial fishers have been successfully transitioned into new roles as official river guardians. This massive conservation effort offers a hopeful, replicable model for global freshwater restoration.
-
Rob Jetten becomes The Netherland’s first openly gay prime minister
In a historic victory for representation and progressive politics, Rob Jetten has been sworn in as the first openly gay Prime Minister of the Netherlands. At 38 years old, the centrist Democrats 66 leader is also the youngest head of government in Dutch history. Jetten successfully formed a minority coalition government following a tense election that defeated far-right populist opponents. His platform prioritizes climate investment, economic fairness, and strong international collaboration. Jetten’s premiership powerfully reaffirms the Netherlands’ global legacy as a pioneer of LGBTQ+ equality and inclusive, cooperative democratic leadership.
-
Millions of New York City workers gain additional time off through new law
Millions of workers in New York City are benefiting from a major expansion of the Protected Time Off Law, which officially took effect in late February 2026. The progressive legislation grants employees an additional 32 hours of unpaid, protected leave that is available immediately upon hire or at the start of the calendar year. This ensures workers do not have to wait to accrue hours before addressing sudden medical emergencies or family crises. The law also vastly expands permitted uses to include mental health care, public disaster recovery, and caring for disabled loved ones.
-
Malaysia bans electronic waste imports to protect the environment and public health
In a monumental victory for public health and environmental justice, Malaysia has enacted an immediate and absolute ban on the importation of electronic waste. By removing regulatory loopholes and launching a strict enforcement campaign, the nation is successfully preventing toxic heavy metals from polluting its soil and waterways. Authorities have already intercepted hundreds of thousands of kilograms of illegal e-waste at major ports, vowing to return the hazardous materials to their countries of origin. This decisive action establishes Malaysia as a leading force in Southeast Asia’s growing movement to reject global waste and prioritize ecological sustainability.